title: No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance.
abstract: BACKGROUND
  rs12979860 and rs8099917 interleukin-28B polymorphisms are associated with spontaneous or interferon-alpha induced hepatitis C clearance, "CC" and "TT" genotypes (respectively) being the most favourable. There are no data on the influence of interleukin-28B polymorphisms on hepatitis delta clearance in hepatitis B/D co-infected patients.
  
  
  OBJECTIVE
  The present study explores the potential influence of both rs12979860 and rs8099917 polymorphisms on delta infection outcome.
  
  
  METHODS
  Retrospective-longitudinal study on 55 European patients observed for at least 4 years, selected from a cohort of 439 subjects positive for hepatitis delta antibodies and hepatitis B core antibodies. The rate of spontaneous and interferon induced delta-RNA clearance was compared in interleukin-28B rs12979860 "CC" vs "non CC", and in rs8099917 "TT" vs "non TT" genotypes.
  
  
  RESULTS
  Prevalence of rs12979860C allele was 60%, consistent with the reported prevalence in Italy (67%, p=0.128). No significant differences in spontaneous clearance rate were observed between rs12979860 "CC" and "non CC" genotypes (13.3% vs 7.5%, respectively, p=0.60), and between rs8099917 "TT" and "non-TT" genotypes (11.1 vs 7.1%, respectively, p=0.67). No differences were observed for interferon-induced delta-RNA clearance either.
  
  
  CONCLUSIONS
  Our data suggest that interleukin-28B polymorphisms might not influence hepatitis delta clearance rate in either natural history or interferon-alpha response.
authors.affiliation: POIT Department, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
authors.forename: Ubaldo
authors.initials: U
authors.lastname: Visco-Comandini
authors.affiliation: Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy. Electronic address: daniele.lapa@inmi.it.
authors.forename: Daniele
authors.initials: D
authors.lastname: Lapa
authors.affiliation: POIT Department, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Taibi
authors.affiliation: Department of Epidemiology and Pre-clinical Research, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Angeletti
authors.affiliation: Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Capobianchi
authors.affiliation: Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.
authors.forename: Anna Rosa
authors.initials: AR
authors.lastname: Garbuglia
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D005838:Genotype; D006508:Hepatitis Antibodies / Q000276:immunology*; D019701:Hepatitis D, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D003698:Hepatitis Delta Virus / Q000235:genetics / Q000276:immunology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D012367:RNA, Viral / Q000097:blood*; D012075:Remission, Spontaneous; D012189:Retrospective Studies; D016896:Treatment Outcome; D019562:Viral Load; D044465:White People; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D006508:Hepatitis Antibodies; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D012367:RNA, Viral; C000624353:interferon-lambda, human; D000095022:Interferon Lambda
keywords: HDV infection; IFN treatment; IL28B; Viral clearance